Patient P-01713
Synthetic patientNBL-101 · Day 107 · 35–44 · F · baseline S04Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Favorable
GI state
Stable
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
49%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S04
- Day 45 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 45 SC-12 recommended — Supportive Compound SC-12
- Day 46 Patient accepted — Started SC-12 in the companion
- Day 52 GI symptom burden −20% vs expected — Supportive Compound SC-12
- Day 57 ME-01 recommended — Monitoring Escalation ME-01
- Day 58 Tolerance state changed — Unstable → Improving
- Day 58 Patient accepted — Started ME-01 in the companion
- Day 60 GI-04 recommended — GI Support Protocol GI-04
- Day 61 Patient accepted — Started GI-04 in the companion
- Day 61 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
- Day 69 GI symptom burden −22% vs expected — GI Support Protocol GI-04
- Day 75 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 45.
Primary contributors, last 14 days
- Toxicity-4
- Inflammatory activity-3
- Nutritional resilience-3
- Treatment adherence+2
What helped?
- Supportive Compound SC-12Day 45Result: symptom burden −20%
- Monitoring Escalation ME-01Day 57Result: deterioration detected before clinical escalation
- GI Support Protocol GI-04Day 60Result: symptom burden −22%
LIFE OS recommendation
Dietary Support Protocol NP-02
54%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 68% showed improvement
- median effect visible after 10 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion45.3/100
improving · -1.7 vs previous 14 d
Toxicity
Blood35.8/100
improving · -3.4 vs previous 14 d
Sleep quality
Wearable44.2/100
improving · +4.4 vs previous 14 d
Energy level
Daily log3.2/10
improving · +0.2 vs previous 14 d
Stress level
Daily log5.9/10
improving · -0.3 vs previous 14 d
Steps
Wearable7,960
stable · +188 vs previous 14 d
Adherence
Companion51.7 %
stable · +0.4 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 37 from the failing basin, 50 from restoration.
Good elements to keep
- Supportive Compound SC-12intervention · steering +34.4
- GI Support Protocol GI-04intervention · steering +32.3
- Monitoring Escalation ME-01intervention · steering +4.7
Main detractors to watch
- Low butyrate capacityhidden · steering -17.5
- Low microbial diversityhidden · steering -7.7
- Bacteroides fragilis elevatedhidden · steering -7.4
- IL6 high-expression varianthidden · steering -7.3
- Dietary fat loaddetractor · GI +3.7 next day
- Spicy / capsaicindetractor · GI +3.1 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load+3.7detractor · 95%
- Spicy / capsaicin+3.1detractor · 81%
- Simple carbohydrates+3detractor · 84%
- Insoluble fibre+1.2no signal · 30%
- Alcohol-0.4no signal · 15%
- Histamine load+0.3no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 41/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 48
- Autonomic recovery ↑45
- WearableResting HR 75 bpm
- WearableShort sleep window
- Mucosal barrier integrity ↓20
- Daily logGI symptom score 45 and rising
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.9 · butyrate capacity 41/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 59 ms
- Sleep
- 6.9 h
- Steps
- 8,092
- Resting HR
- 75 bpm
Daily log: GI score 45, nutritional resilience 44, adherence 52.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.